<DOC>
	<DOCNO>NCT02171117</DOCNO>
	<brief_summary>Patients enrol center accord confirm criterion specify cooperative scheme randomly assign standard induction consolidation chemotherapy microtransplantation （MST-group）or without ( CT-group ) .Compare remission rate 2-year disease-free survival ( DFS ) overall survival ( OS ) rate two group .</brief_summary>
	<brief_title>Safety Efficacy Study Microtransplantation Treat Elderly Acute Myeloid Leukemia</brief_title>
	<detailed_description>Microtransplantation , combine chemotherapy adoptive infusion granulocyte colony stimulate factor ( G-CSF ) mobilize HLA-mismatched peripheral blood stem cell ( GPBSC ) . Data 70 elderly AML patient receive microtransplantation Beijing show remission rate 2-year disease-free survival ( DFS ) reach 75-82 % 32-39 % respectively , microchimerisms ( donor cell &lt; 1 % ) detect without GVHD . The result clinically validate several center China , United States Australia . Based fact , validate therapeutic efficacy , propose phase III clinical trial de novo AML patient ≥60 year old randomly assign receive standard induction consolidation chemotherapy without microtransplantation .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Patients must elderly ( 6085 age ) AML pathologically confirm per WHO guideline . Patients treat . Patients must ECOG Performance status 0,1 , 2 . If ECOG 2 . Patients must HLA mismatch donor able provide inform consent . All gender race eligible . ALT AST≤3 ×ULN , TBIL≤1.5 × ULN , Cr≤2 ×ULN CrCl≥40 mL/min By mean ultrasonic Heartbeat map multiple gated acquisition ( MUGA ) scan determination LVEF normal range . Donors must able safely undergo leukapheresis . receive operation 4 week randomization acute promyelocytic leukemia , Myeloid sarcoma , chronic myeloid leukemia accelerate phase blastic phase ; active CNS disease , pregnancy , major medical psychiatric illness could compromise tolerance protocol occur stroke intracranial hemorrhage within 6 month randomization . Require use warfarin equivalent vitamin K antagonist ( phenprocoumon ) anticoagulant . There clinical significance cardiovascular disease , uncontrolled symptomatic arrhythmia , congestive heart failure myocardial infarction within 6 month randomization , heart function grade 3 ( moderate ) 4 ( severe ) heart disease accordance functional classification method New York Heart Association ( NYHA ) . Known follow history : human immunodeficiency virus ( HIV ) active hepatitis C virus hepatitis B virus infection Any situation process PI damage patient safety . Patients / authorized family member refuse sign consent . attend clinical researcher 3 month . Donors exclusion criterion include : active infection malignancy , cardiovascular instability , severe anemia , severe coagulation disorder , pregnancy , inadequate venous access , inability provide consent , condition deem unsafe treatment staff .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>microtransplantation</keyword>
	<keyword>elderly patient</keyword>
	<keyword>HLA-mismatched</keyword>
	<keyword>donor</keyword>
	<keyword>Peripheral</keyword>
	<keyword>stem cell</keyword>
	<keyword>infusion</keyword>
</DOC>